Roche celebrates the induction of new oncology nurses in Ghana

Roche celebrates the induction of new oncology nurses in Ghana

Roche celebrates the induction of new oncology nurses in Ghana.

  • Six students specializing in oncology nursing, who benefitted from the Roche emerging market scholarship program, graduated from the Ghana College of Nurses and Midwives (GCNM)
  • In total, Roche is supporting 26 oncology nurses at GCNM to help improve cancer care in Ghana

Accra, Ghana, 17 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the first cohort of six Roche-sponsored oncology nursing students graduated from the Ghana College of Nurses and Midwives (GCNM). As part of the GCNM mandate, these specialists are committed to providing high-level, evidence-based cancer care in Ghana.

Advertisement

“We are very proud of the oncology nursing graduates for this important accomplishment,” said Philip Anderson, General Manager of Roche Ghana. “The oncology nurse has such an important role in the journey of a cancer patient. Roche is committed to improving the standard of care for patients in Ghana and this is an important step.”

“Over the years, the incidence of various cancers has increased globally and Ghana is not an exception. Most Ghanaians with cancer report to the hospital late and this increases the burden of care for the few specialists providing oncology care,” said Hannah Acquah, GCNM Rector. “This is why we are committed to develop a cadre of specialist oncology nurses who will be equipped to provide high-level cancer care to our patients and improve our healthcare environment.”

When Roche began supporting oncology nurses at GCNM in 2017, there were only 12 oncology nurses practicing in the country’s cancer treatment centers. In total, Roche is providing 26 oncology-nursing scholarships, which will more than triple the number of oncology nurses in Ghana. These specialists will not only help to improve care for their cancer patients, the will also help to bridge gaps in oncology skills and ultimately enhance the outcome of healthcare in Ghana.

The Roche GCNM scholarships include fees for admission, tuition and examination as well as stipends to cover clinical kits, diagnostic sets, lodging, travel and examination for three years of the residency program. In addition, the Roche beneficiaries also receive support to attend oncology-related conferences. The cohort timelines are as follows: 6 students (2017-2020), 10 students (2018-2021) and 10 students (2019-2022).

This is part of Roche Corporate Donations and Philanthropy’s emerging market scholarship program, which supports higher education for young talents across the globe. Roche began the five-year collaboration with GCNM in 2017. Roche is providing these oncology nurse scholarships through the Fondation Roche de Recherche en Afrique, which supports research and education based projects in Africa.



About the Ghana College of Nurses and Midwives
The Ghana College of Nurses and Midwives (GCNM) promotes specialist education, continuous professional development and postgraduate nursing, midwifery and related programs as well as contribute to the formulation of policies to improve health outcomes. The goal of the College is to develop a cutting-edge cadre of nurses and midwives with higher education, who are motivated to lead and develop the future of nurses and midwifery as specialist clinicians, academicians, researchers and mangers in Ghana, Africa and beyond.

About Roche Ghana
Roche Products Ghana Ltd, a limited liability company formed and duly incorporated under the laws of Ghana since 2000 and is an affiliate of F. Hoffmann La-Roche Limited.  The local affiliate is committed to providing patients access to their innovation and removing barriers to healthcare. Through a combination of products, services and systems—including awareness and understanding, infrastructure and people capabilities, and a shared commitment to healthcare—we aim to make a real difference in the lives of patients in Ghana.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognized as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Ghana Contact Information

Dr. Louisa Preko
Medical Director Ghana
+ (233) 55 257 0782
louisa.preko@roche.com 

EDITOR's NOTE: This is an advertorial

Connect With Us : 0242202447 | 0551484843 | 0266361755 | 059 199 7513 |

Like what you see?

Hit the buttons below to follow us, you won't regret it...

0
Shares